ReviewCancer immunology, immunotherapy : CII2012
Prothymosin alpha: a ubiquitous polypeptide with potential use in cancer diagnosis and therapy.
Review in Cancer immunology, immunotherapy : CII, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 47 citations in OpenAlex.
- A Multi-omics and Machine Learning Framework Identifies Plasma SBDS as a Causal Biomarker and Therapeutic Target in Primary Sclerosing Cholangitis.Journal of clinical and translational hepatology · 2026Article
- Proteomic Analysis of Invasive Breast Cancer Cells Treated with CBD Reveals Proteins Associated with the Reversal of Their Epithelial-Mesenchymal Transition Induced by IL-1β.International journal of molecular sciences · 2025Article
- KEAP1-NRF2 Interaction in Cancer: Competitive Interactors and Their Role in Carcinogenesis.Cancers · 2025Review
- Thymosin α1 Combined with PD-1/PD-L1 Inhibitor Plus Chemotherapy in Platinum-Resistant Recurrent Ovarian Cancer : A Retrospective Analysis.Cancer management and research · 2025Article
- Pancancer landscape analysis of the thymosin family identified TMSB10 as a potential prognostic biomarker and immunotherapy target in glioma.Cancer cell international · 2022Article
- Immunoregulatory therapy strategies that target cytokine storms in patients with COVID-19 (Review).Experimental and therapeutic medicine · 2021Review
- Hexapeptide derived from prothymosin alpha attenuates cisplatin-induced acute kidney injury.Clinical and experimental nephrology · 2020Article
- A fragment of the alarmin prothymosin α as a novel biomarker in murine models of bacteria-induced sepsis.Oncotarget · 2017Article
- Prothymosin Alpha and Immune Responses: Are We Close to Potential Clinical Applications?Vitamins and hormones · 2016Review
- Role of EBNA-3 Family Proteins in EBV Associated B-cell Lymphomagenesis.Frontiers in microbiology · 2016Review
- Single Cell RNA-Sequencing of Pluripotent States Unlocks Modular Transcriptional Variation.Cell stem cell · 2015Article
- Prothymosin α variants isolated from CD8+ T cells and cervicovaginal fluid suppress HIV-1 replication through type I interferon induction.The Journal of infectious diseases · 2015Article
- ISO-66, a novel inhibitor of macrophage migration, shows efficacy in melanoma and colon cancer models.International journal of oncology · 2014Article
- Increased expression of prothymosin-α, independently or combined with TP53, correlates with poor prognosis in colorectal cancer.International journal of clinical and experimental pathology · 2014Article
- Prothymosin α and a prothymosin α-derived peptide enhance T(H)1-type immune responses against defined HER-2/neu epitopes.BMC immunology · 2013Article
- Quantitative Proteomics Identifies Activation of Hallmark Pathways of Cancer in Patient Melanoma.Journal of proteomics & bioinformatics · 2013Article
- Prothymosin α overexpression contributes to the development of pulmonary emphysema.Nature communications · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The thymus is a central lymphoid organ with crucial role in generating T cells and maintaining homeostasis of the immune system. More than 30 peptides, initially referred to as "thymic hormones," are produced by this gland. Although the majority of them have not been proven to be thymus-specific, thymic peptides comprise an effective group of regulators, mediating important immune functions. Thymosin fraction five (TFV) was the first thymic extract shown to stimulate lymphocyte proliferation and differentiation. Subsequent fractionation of TFV led to the isolation and characterization of a series of immunoactive peptides/polypeptides, members of the thymosin family. Extensive research on prothymosin α (proTα) and thymosin α1 (Tα1) showed that they are of clinical significance and potential medical use. They may serve as molecular markers for cancer prognosis and/or as therapeutic agents for treating immunodeficiencies, autoimmune diseases and malignancies. Although the molecular mechanisms underlying their effect are yet not fully elucidated, proTα and Tα1 could be considered as candidates for cancer immunotherapy. In this review, we will focus in principle on the eventual clinical utility of proTα, both as a tumor biomarker and in triggering anticancer immune responses. Considering the experience acquired via the use of Tα1 to treat cancer patients, we will also discuss potential approaches for the future introduction of proTα into the clinical setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.